Fc receptor-mediated antiviral antibodies
- 1 September 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 4 (5) , 388-393
- https://doi.org/10.1097/coh.0b013e32832f0a89
Abstract
Purpose of review We summarize current information on Fc receptor-mediated antiviral activities of antibodies. These activities include Fcγ receptor-mediated inhibition and neutralization of HIV on antigen-presenting cells, antibody-dependent cellular cytotoxicity, and antibody-dependent cell-mediated virus inhibition (ADCVI). Recent findings An Fcγ receptor-mediated mechanism that results in augmented neutralization and may render nonneutralizing antibodies inhibitory has been demonstrated in antigen-presenting cell. Antibody-dependent cellular cytotoxicity antibody activity correlates inversely with HIV disease progression in humans, and higher vaccine-induced antibody-dependent cellular cytotoxicity antibody responses are associated with lower acute simian immunodeficiency virus viremia levels in macaques. Following vaccination with rgp120, ADCVI antibody levels are higher among those with a lower rate of sexually acquired HIV infection. Nonneutralizing simian immunodeficiency virus immune serum that prevents infection of newborn macaques after oral challenge has potent ADCVI antibody activity. Abrogating the ability of the Fc segment of the broadly neutralizing mAb b12 to bind to Fcγ receptors and to mediate ADCVI substantially reduces b12's protective effect in a simian/human immunodeficiency virus vaginal challenge model. Summary Fc–FcγR interactions play a critical role in the biological function of antibody and are likely to be instrumental in preventing or modulating lentiviral infection. Exploiting antibody responses that depend on Fc–FcγR interactions may help widen the breadth and increase the potency of vaccine-induced antibody. Although the importance of generating optimal Fab–antigen interactions cannot be overestimated, improving Fc–FcγR interactions through adjuvants or other strategies provides another option for improving HIV vaccines and immunotherapies.Keywords
This publication has 52 references indexed in Scilit:
- Utilization of Immunoglobulin G Fc Receptors by Human Immunodeficiency Virus Type 1: a Specific Role for Antibodies against the Membrane-Proximal External Region of gp41Journal of Virology, 2009
- Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllersAIDS, 2009
- Correlation of Vaccine-Elicited Systemic and Mucosal Nonneutralizing Antibody Activities with Reduced Acute Viremia following Intrarectal Simian Immunodeficiency Virus SIV mac251 Challenge of Rhesus MacaquesJournal of Virology, 2009
- Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial ViremiaJournal of Virology, 2008
- Cross-Reactive Human Immunodeficiency Virus Type 1-Neutralizing Human Monoclonal Antibody That Recognizes a Novel Conformational Epitope on gp41 and Lacks Reactivity against Self-AntigensJournal of Virology, 2008
- Robust NK Cell-Mediated Human Immunodeficiency Virus (HIV)-Specific Antibody-Dependent Responses in HIV-Infected SubjectsJournal of Virology, 2008
- FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patientsCancer Genetics and Cytogenetics, 2008
- Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C InfectionJournal of Virology, 2007
- Rhesus Macaque Polyclonal and Monoclonal Antibodies Inhibit Simian Immunodeficiency Virus in the Presence of Human or Autologous Rhesus Effector CellsJournal of Virology, 2006
- Nonneutralizing Antibodies Are Able To Inhibit Human Immunodeficiency Virus Type 1 Replication in Macrophages and Immature Dendritic CellsJournal of Virology, 2006